A pharmaceutical composition can include a plurality of liposomes comprising docetaxel and doxorubicin. In various embodiments a liposome can include (i) an active pharmaceutical ingredient (API) comprising docetaxel and doxorubicin (ii) a lipid layer comprising an unsaturated phospholipid a cholesterol a cationic lipid and preferably a pegylated phospholipid and (iii) an aqueous interior wherein the docetaxel is in the lipid layer and the doxorubicin is crystallized in the aqueous interior. The liposomes can be used to treat a subject for example a human subject having cancer. The cancer can be for example a lung cancer preferably non small cell lung cancer (NSCLC) colon cancer breast cancer or liver cancer.
